Lipid nanoparticles (LNPs) have transformed RNA therapeutics through their high delivery efficiency, scalable manufacturing, and favorable safety profiles, as demonstrated by COVID-19 mRNA vaccines and clinically approved small interfering RNA (siRNA) therapeutics. However, extending RNA delivery beyond the liver to ex...
Jia-Xin Li, Jian-Ping Liu, Nan Wang et al.· Advances in Materials· 1 citation
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.